Delivery Order SPE2DE24D0013-SPE2D625F0YLJ
- Not listed
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded Cepheid Inc. a delivery order valued at $22,240 on September 9, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV). This firm fixed-price delivery order, which has no set-aside designation, is scheduled for completion by September 16, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. Cepheid is a for-profit...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain program, awarded a $8,995.14 firm fixed-price delivery order to Cepheid Inc. on May 6, 2025, for molecular diagnostic solutions with an ultimate completion date of May 13, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, references testing capabilities for COVID-19, influenza, and respiratory syncytial virus (RSV)—aligning with Cepheid's core diagnostic product offerings. The contract carries no set-aside...
- This delivery order, valued at $40,800, was awarded to Cepheid Inc. on August 25, 2025, by the Defense Logistics Agency's Medical Supply Chain division for the provision of molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract carries a firm fixed-price structure with no set-aside designation and is scheduled for completion by September 2, 2025. Cepheid, a Sunnyvale, California-based manufacturer specializing in molecular...
- This delivery order, valued at $6,800, was awarded to Cepheid Inc. on September 4, 2025, by the Medical Supply Chain, a defense-focused federal agency. The contract covers molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection, with performance to be completed at Cepheid's Sunnyvale, California facility by September 11, 2025. The award carries a firm fixed-price structure with no set-aside designation, indicating competitive procurement....
- The Defense Logistics Agency awarded a $12,240 firm fixed-price delivery order to Cepheid Inc. for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, with an ultimate completion date of August 15, 2025, was awarded on August 8, 2025, with no set-aside designation. Cepheid, a Sunnyvale, California-based manufacturer specializing in molecular diagnostic systems and test kits, will perform the work at its California...
- The U.S. Defense Department's Medical Supply Chain organization awarded a $2,835 firm fixed-price delivery order to Cepheid Inc. on August 29, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, which extends through September 8, 2025, will be performed at Cepheid's facility in Sunnyvale, California. This award carries no small business set-aside designation and represents a continuation of...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain division, awarded a $14,448 firm fixed-price delivery order to Cepheid Inc. on September 8, 2025, with an ultimate completion date of September 15, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic testing solutions, specifically for COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The contract carries no set-aside designation and will be performed at Cepheid's...
- The U.S. Defense Department's Medical Supply Chain agency awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. on July 14, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, which is due for completion by July 21, 2025, utilizes no set-aside designation and will be performed at Cepheid's facility in Sunnyvale, California. This delivery order represents a continuation of Cepheid's established role as...
- The U.S. Defense Department's Medical Supply Chain division awarded a $6,800 firm fixed-price delivery order to Cepheid Inc. (Sunnyvale, CA) on April 23, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated XPCOV2/FLU/RSV-10, carries an ultimate completion date of April 30, 2025, and involves no set-aside provisions. This delivery order represents procurement activity under Cepheid's existing indefinite...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain function, awarded a $20.4K firm fixed-price delivery order to Cepheid Inc. on September 18, 2025, with a completion date of September 25, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic solutions for COVID-19, influenza, and respiratory syncytial virus (RSV) testing, with performance to be executed at Cepheid's facility in Sunnyvale, California. This award carries no set-aside...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F0YLJDelivery Order
This delivery order, valued at $19,047.16, was awarded to Cepheid Inc. on August 13, 2025, by the Defense Logistics Agency (operating under the Medical Supply Chain program) for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract is a firm fixed-price arrangement with no set-aside designation and is scheduled for completion by August 20, 2025. Performance will take place at Cepheid's facility in Sunnyvale, California. Cepheid specializes in advanced molecular diagnostic systems and test kits, leveraging its GeneXpert diagnostic platform to deliver testing solutions across federal healthcare systems. This delivery order likely represents a task order issued under one of Cepheid's existing Indefinite Delivery/Indefinite Quantity (IDIQ) contracts, which provide the company with standing authorization to supply molecular diagnostic reagents, assays, and testing services to federal agencies. Cepheid maintains significant IDQ vehicles with the Department of Veterans Affairs, including a single-award contract valued at $32.8 million through September 2030, which covers diagnostic testing system reagents and assays for conditions including COVID-19, influenza, RSV, and other infectious diseases. The company's federal contracting history demonstrates consistent demand for its diagnostic capabilities across multiple defense and civilian health agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.0k | 8/13/25 |